In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
May, 2021: Novartis to expand and strengthen its antibiotic manufacturing business in Europe.
July, 2019: Mylan N.V. and Upjohn, a subdivision of Pfizer Inc. collectively established a new pharmaceutical company, Vitaris Inc.
The global necrotizing gingivostomatitis treatment market is estimated to grow at a significant CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing prevalence of necrotizing gingivostomatitis, especially amongst the Caucasian population. The disorder is caused by various predisposing factors, including, poor oral hygiene, smoking and drinking, unusual life stress, inadequate sleep, and others. The degrading lifestyle of the population is estimated to boost the market growth. Weakened immune system, backed by widespread infectious diseases, is another major cause of necrotizing gingivostomatitis. The increasing investment in the R&D activities in the medical field, along with rising health awareness amongst the people is estimated to boost the market growth. Moreover, the developing public healthcare infrastructure and high government expenditure for the development of new drugs is anticipated to significantly fuel the growth of the market.
Get more information on this report: Download Sample PDF
The market is segmented by type into necrotizing ulcerative gingivitis (NUG), necrotizing ulcerative periodontitis (NUP), and necrotizing stomatitis (NS), out of which, the necrotizing ulcerative gingivitis (NUG) segment is anticipated to hold the largest share in the global necrotizing gingivostomatitis treatment market over the forecast period on account of growing prevalence of the disease, backed by poor oral health. It is the most common type of necrotizing gingivostomatitis.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global necrotizing gingivostomatitis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Europe region is estimated to witness noteworthy growth over the forecast period on the back of large Caucasian population, and poor lifestyle of the people in developed nations. Over 50 million people in Europe suffer with chronic conditions. Similarly, the market in the North America region is anticipated to gain the largest market share throughout the forecast period, on the back of high prevalence of lifestyle diseases, caused by inactive routine, busy lifestyle, and unhealthy eating habits. According to the data by the Center of Disease Control and Prevention, over 45% of the Americans suffer from at least one chronic disease.
Get more information on this report: Download Sample PDF
The global necrotizing gingivostomatitis treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global necrotizing gingivostomatitis treatment market includes the following segments:
By Distribution Channel
Ans: Increasing incidences of necrotizing gingivostomatitis is estimated to boost the market growth.
Ans: The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2030.
Ans: Circulation of generic drugs is estimated to hamper the market growth.
Ans: The market in the North America region is estimated to provide more business opportunities owing to the vast Caucasian population.
Ans: The major players in the market are Mylan N.V., Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd, Abbott Laboratories, Eli Lilly and Company, and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by type, treatment, distribution channel, and by region.
Ans: The antibiotics segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.